SELLAS Life Sciences shares are trading higher after the company was granted FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor for the treatment of pediatric acute lymphoblastic leukemia, making it eligible for a priority review voucher worth over $100 million upon approval.
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences shares are trading higher after the company was granted FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor for the treatment of pediatric acute lymphoblastic leukemia. This designation makes the company eligible for a priority review voucher worth over $100 million upon approval.
June 24, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences shares are trading higher after receiving FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor, which makes it eligible for a priority review voucher worth over $100 million upon approval.
The FDA Rare Pediatric Disease Designation is a significant milestone for SELLAS Life Sciences, as it not only validates the potential of their SLS009 CDK9 inhibitor but also makes the company eligible for a priority review voucher worth over $100 million. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100